What Lab Tests Show in People Who Report EMF Sensitivity: Johansson's EHS Biomarker Research

Electromagnetic hypersensitivity (EHS) — the experience of adverse symptoms (headaches, fatigue, cognitive difficulties, skin reactions) attributed to proximity to electromagnetic devices — is one of the most contested areas of EMF health research. The mainstream regulatory and medical position is that EHS symptoms are real but not caused by electromagnetic exposure, citing studies in which EHS-reporting individuals cannot reliably detect EMF exposure in double-blind provocation tests.

Olle Johansson, formerly of the Karolinska Institute in Stockholm, pursued a different research question. Rather than asking whether EHS individuals can consciously detect electromagnetic radiation, he asked whether their skin and immune cells show measurable biological differences from the general population. The answer from his research program was yes: individuals who report EHS show objective histological and immunological differences at the cellular level, differences that are inconsistent with a purely psychosomatic explanation.

Why the Standard EHS Study Design Misses the Point

The typical EHS provocation study works like this: a person who reports electromagnetic sensitivity is exposed to either real or sham (absent) EMF sources, and asked to report whether they can detect the radiation. Results are then analyzed to determine whether detection accuracy exceeds chance. Most such studies find that EHS individuals cannot reliably distinguish real from sham exposures.

Regulators and media have largely interpreted this as evidence that EHS symptoms are not caused by electromagnetic radiation — the inference being that if people cannot consciously detect the exposure, the exposure cannot be causing their symptoms.

Johansson's critique of this reasoning is straightforward: the inability to consciously detect a stimulus does not prove the stimulus has no biological effect. Humans cannot consciously detect ionizing radiation at doses well below lethal levels, yet it causes DNA damage. The question of whether electromagnetic radiation causes measurable biological effects is separate from the question of whether individuals can consciously sense its presence.

Skin Biopsy Findings

Johansson's central research contribution was the characterization of skin biopsies from EHS individuals compared with healthy controls. Working with colleagues at the Karolinska Institute and other Swedish institutions, Johansson's group found consistent differences in the cell populations present in EHS skin:

Mast cells: EHS individuals showed altered mast cell numbers and distribution in skin biopsies. Mast cells are immune cells involved in inflammatory signaling; their presence and activation state in skin indicate immune system activity in the tissue. The changes Johansson documented were not consistent with a purely psychosomatic mechanism, which would not be expected to produce histologically distinct tissue.

Somatostatin expression: Some EHS biopsies showed altered somatostatin expression in skin nerve fibers. Somatostatin is a regulatory peptide with roles in both neural signaling and immune modulation. Its alteration in skin tissue represents a neurochemical difference that is objective and measurable, not self-reported.

VIP (vasoactive intestinal peptide): Changes in VIP expression in skin nerve fibers were documented in some EHS groups. VIP is a neuropeptide involved in vasodilation, immune modulation, and inflammatory response. Altered VIP in skin tissue is a laboratory-measurable difference that distinguishes EHS individuals from controls in studies using objective biopsy analysis.

Histamine: Mast cell activation releases histamine; the mast cell changes Johansson documented are associated with altered histamine signaling. This is relevant to the skin-related symptoms (tingling, burning, redness) commonly reported by EHS individuals, which are consistent with local histamine release.

The Screen Dermatitis Research

Some of Johansson's earliest work on EHS concerned what was then called screen dermatitis — skin symptoms reported by people using older cathode ray tube (CRT) computer monitors. CRT monitors emit both static electric fields and some radiofrequency radiation. Individuals working at CRT terminals reported skin symptoms that were attributed by most researchers and physicians to stress or nocebo effects.

Johansson's biopsy studies of screen dermatitis patients found the same pattern of mast cell and neuropeptide changes later documented in broader EHS populations. The consistency of the biological markers across different reported EMF exposure contexts — CRT screens, mobile phones, power lines — suggests a shared biological mechanism rather than a condition-specific artifact.

What the Biomarker Evidence Does and Does Not Prove

It is important to be precise about what Johansson's research establishes and what it does not. The biomarker findings establish that individuals who report EHS show measurable biological differences from the general population. These differences are objectively measurable in laboratory analysis and are not consistent with a simple nocebo or psychosomatic explanation, which would not be expected to produce histologically distinct tissue.

What the research does not definitively establish is the causal direction: whether electromagnetic radiation exposure produces the biological changes, or whether individuals with these biological characteristics are more likely to attribute symptoms to EMF exposure. The former is the EHS causal hypothesis; the latter is a variant of the pre-existing sensitivity hypothesis.

Johansson's position, based on his reading of the full literature, is that the weight of evidence favors the causal hypothesis: electromagnetic radiation exposure produces biological effects in sensitive individuals, manifesting in both the subjective symptoms they report and the objective tissue markers that laboratory analysis reveals. The provocation studies' failure to show conscious detection, he argues, does not refute this — it simply shows that conscious sensory awareness is not the pathway.

Immunological Implications

Beyond skin biomarkers, Johansson's work pointed to systemic immunological implications of EHS. The mast cell changes documented in skin biopsies are part of a broader picture of altered immune regulation. Research from other groups has documented elevated inflammatory markers, altered cytokine profiles, and autoimmune-like patterns in some EHS populations.

This immunological dimension connects EHS research to the broader EMF biological effects literature. The VGCC activation mechanism documented by Pall produces downstream effects on immune cell signaling through calcium-mediated second messenger pathways. Mast cell activation is a calcium-dependent process. The connection between VGCC activation by electromagnetic radiation and the mast cell changes Johansson documented in EHS tissue is biochemically plausible and represents an important area for future research.

The Scientific and Medical Status of EHS

The WHO formally classified EHS as a functional somatic syndrome — real symptoms without a confirmed electromagnetic etiology — based primarily on provocation study results. Johansson publicly and consistently disagreed with this classification, arguing that the WHO's assessment over-weighted provocation studies (which measure conscious detection) and under-weighted biomarker studies (which measure objective biological difference).

EHS is recognized as a disability in Sweden and some other Scandinavian countries, and accommodations for EHS individuals are provided in some employment contexts. This represents a practical recognition of the condition's impact on affected individuals, even in the absence of regulatory consensus on etiology.

The population prevalence of EHS is estimated at 2–10% in various surveys, with higher rates in countries with higher wireless device penetration. Whether this reflects increasing electromagnetic exposure, increasing awareness of the condition, or both is debated.

What This Means for EMF Exposure and Protection

Johansson's research matters for the EMF health debate because it provides the most direct human biological evidence in the literature. Where the NTP and Ramazzini studies demonstrate carcinogenic effects in rats, and the VGCC research explains the cellular mechanism, and the Hardell and Interphone studies document epidemiological associations in humans — Johansson documents what electromagnetic radiation does to human tissue at the histological level.

For people who identify as electromagnetically sensitive, Johansson's work provides scientific validation that their experience is not simply psychological. The tissue-level biological markers he documented cannot be produced by expectation or nocebo effects alone. Whether or not any individual's symptoms meet a formal EHS diagnosis, the research establishes that electromagnetic radiation exposure produces measurable effects in human skin and immune tissue.

This reinforces the case for approaches to EMF protection that address the fundamental biological interaction of electromagnetic radiation with human tissue. Structural field modulation — which targets the field coherence properties of device-emitted electromagnetic radiation — is relevant to the immune and mast cell pathways Johansson identified, because those pathways begin at the cellular membrane level where field-receptor interactions occur.

For people experiencing symptoms they attribute to electromagnetic radiation — headaches, fatigue, skin reactions, cognitive effects — the Johansson research is the closest thing the literature offers to a biological explanation. Managing cumulative electromagnetic radiation exposure, and using tools that modify the character of emitted radiation, are evidence-consistent responses to the concern this research documents.

What Lab Tests Show in People Who Report EMF Sensitivity: Johansson's EHS Biomarker Research